PT  - JOURNAL ARTICLE
AU  - Solís Arce, Julio S.
AU  - Warren, Shana S.
AU  - Meriggi, Niccoló F.
AU  - Scacco, Alexandra
AU  - McMurry, Nina
AU  - Voors, Maarten
AU  - Syunyaev, Georgiy
AU  - Malik, Amyn Abdul
AU  - Aboutajdine, Samya
AU  - Armand, Alex
AU  - Asad, Saher
AU  - Augsburg, Britta
AU  - Bancalari, Antonella
AU  - Nyqvist, Martina Björkman
AU  - Borisova, Ekaterina
AU  - Bosancianu, Constantin Manuel
AU  - Cheema, Ali
AU  - Collins, Elliott
AU  - Farooqi, Ahsan Zia
AU  - Fracchia, Mattia
AU  - Guariso, Andrea
AU  - Hasanain, Ali
AU  - Kamwesigye, Anthony
AU  - Kreps, Sarah
AU  - Levine, Madison
AU  - Littman, Rebecca
AU  - Platas, Melina
AU  - Ramakrishna, Vasudha
AU  - Shapiro, Jacob N.
AU  - Svensson, Jakob
AU  - Vernot, Corey
AU  - Vicente, Pedro C.
AU  - Weissinger, Laurin B
AU  - Zhang, Baobao
AU  - Karlan, Dean
AU  - Callen, Michael
AU  - Teachout, Matthieu
AU  - Humphreys, Macartan
AU  - Omer, Saad B.
AU  - Mobarak, Ahmed Mushfiq
TI  - COVID-19 Vaccine Acceptance and Hesitancy in Low and Middle Income Countries, and Implications for Messaging
AID  - 10.1101/2021.03.11.21253419
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.11.21253419
4099  - http://medrxiv.org/content/early/2021/05/12/2021.03.11.21253419.short
4100  - http://medrxiv.org/content/early/2021/05/12/2021.03.11.21253419.full
AB  - We analyze COVID-19 vaccine acceptance across 15 survey samples covering ten low- and middle-income countries (LMICs) in Asia, Africa, and South America, Russia (an upper-middle-income country), and the United States, using survey responses from 44,260 individuals. We find considerably higher willingness to take a COVID-19 vaccine in LMIC samples (80% on average) compared to the United States (65%) and Russia (30%). Vaccine acceptance was primarily explained by an interest in personal protection against COVID-19, while concern about side effects was the most commonly expressed reason for reluctance. Health workers were the most trusted sources of information about COVID-19 vaccines. Our findings suggest that prioritizing vaccine distribution to LMICs should yield high returns in promoting global immunization coverage, and that vaccination campaigns in these countries should focus on translating acceptance into uptake. Messaging highlighting vaccine efficacy and safety, delivered by healthcare workers, may be most effective in addressing remaining hesitancy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementBeyond Conflict, Bill and Melinda Gates Foundation, Columbia University, Givewell.org, Ghent University, HSE University Basic Research Program, International Growth Centre, Jameel Poverty Action Lab Crime and Violence Initiative, London School of Economics and Political Science, Mulago Foundation, NOVAFRICA at the Nova School of Business and Economics, NYU Abu Dhabi, Oxford Policy Management, Social Science Research Council, Trinity College Dublin COVID19 Response Funding, UK Aid, UKRI GCRF/Newton Fund, United Nations Office for Project Services, Weiss Family Fund, WZB Berlin Social Science Center, Yale Institute for Global Health, Yale Macmillan Center, and anonymous donors to IPA and Y-RISE.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by multiple IRBs and they are listed in the appendix.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and output of the analysis can be consulted here https://wzb-ipi.github.io/covid_vaccines/replication.html. https://wzb-ipi.github.io/covid_vaccines/replication.html